Starfish Ventures in $US40m gastro drug breakthrough

  |   Written By by admin ON

[1] Protagonist, a Melbourne-based venture capital firm and Starfish Ventures-backed life-science company, has hit $US40 million in series C funding for an oral peptide drug for gastrointestinal diseases and disorders.

[2] Starfish Ventures founder Michael Panaccio describes the drug, which has only been subject to animal testing, as a “new wave of medicine”.

[3] The drug has huge potential in developing the platform technology for human testing.

5

[Source] Australian Information Technology News – Starfish Ventures in $US40m gastro drug breakthrough